PMID- 23706065
OWN - NLM
STAT- MEDLINE
DCOM- 20140211
LR  - 20130722
IS  - 1746-045X (Electronic)
IS  - 1746-0441 (Linking)
VI  - 8
IP  - 8
DP  - 2013 Aug
TI  - Novel routes to bipolar disorder drug discovery.
PG  - 907-18
LID - 10.1517/17460441.2013.804057 [doi]
AB  - INTRODUCTION: Bipolar disorder (BD) is a severe and chronic medical condition 
      typified by episodic recurrent mania (or hypomania) in addition to major 
      depression. BD is associated with a number of negative outcomes including 
      premature death, reduced quality of life and can also lead to other complications 
      including impaired cognitive function. Unfortunately, the currently available 
      pharmacological treatments for BD are insufficient for many with the condition. 
      AREAS COVERED: This review focuses on known therapeutic targets of mood 
      stabilizing drugs including: the glycogen synthase kinase-3 (GSK-3), the 
      phosphoinositide pathway and protein kinase C (PKC), the brain-derived 
      neurotrophic factor (BDNF), and histone deacetylases (HDACs). This article also 
      presents new promising therapeutic targets including: the glutamatergic pathway, 
      mitochondrial modulators, neuropeptide-converting endopeptidases, the insulin 
      transduction pathway, the purinergic system and the melatoninergic system. EXPERT 
      OPINION: Challenges in improving methods and tools to generate, integrate and 
      analyze high-dimensional data are required to allow opening novel routes to BD 
      drug discovery. Through the application of systems biology approaches and the use 
      of bioinformatical tools to integrate all omics data, it will be possible in the 
      near future to gain deeper insights into pathophysiology of BD. This will in turn 
      lead to the identification and exploitation of new potential therapeutic 
      approaches.
FAU - Hoertel, Nicolas
AU  - Hoertel N
AD  - Assistance Publique-Hopitaux de Paris (AP-HP), Hopital Corentin-Celton, Service 
      de psychiatrie, Issy-les-Moulineaux, Paris, France.
FAU - de Maricourt, Pierre
AU  - de Maricourt P
FAU - Gorwood, Philip
AU  - Gorwood P
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20130527
PL  - England
TA  - Expert Opin Drug Discov
JT  - Expert opinion on drug discovery
JID - 101295755
RN  - 0 (Psychotropic Drugs)
SB  - IM
MH  - Animals
MH  - Bipolar Disorder/*drug therapy/metabolism
MH  - Drug Discovery
MH  - Humans
MH  - Psychotropic Drugs/*therapeutic use
EDAT- 2013/05/28 06:00
MHDA- 2014/02/12 06:00
CRDT- 2013/05/28 06:00
PHST- 2013/05/28 06:00 [entrez]
PHST- 2013/05/28 06:00 [pubmed]
PHST- 2014/02/12 06:00 [medline]
AID - 10.1517/17460441.2013.804057 [doi]
PST - ppublish
SO  - Expert Opin Drug Discov. 2013 Aug;8(8):907-18. doi: 10.1517/17460441.2013.804057. 
      Epub 2013 May 27.